# US 2017/0290792 A1 · Butyrate and beta-hydroxybutyrate compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0290792 A1
- Document ID: US20170290792A1
- Status: Published application
- Kind: A1
- Application number: 15/187,823
- Filed: 2016-06-21
- Published: 2017-10-12
- Earliest claimed: 2016-04-03
- Inventors: Franco Cavaleri
- Web page: https://patentgrep.com/patent/US20170290792A1

## CPC

- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 36/82: Theaceae (Tea family), e.g. camellia
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Compositions and methods for providing a person with an exogenous and therapeutically effective supply of ketones are disclosed. The compositions may consist essentially of (a) purified butyrate (or esters or propionate salts thereof) and (b) purified beta-hydroxybutyrate (or esters or propionate salts thereof). The compositions may further include other pharmacologically active agents, such as acetyl-L carnitine, R-alpha lipoic acid, green tea extract, vitamins, and various combinations of such agents. The methods include providing a person with an exogenous supply of ketones, by orally administering a pharmacologic composition, which is effective to deliver 2000-5000 mg of a short chain fatty acid (e.g., butyrate) and 5000-10,000 mg of ketone (e.g., beta-hydroxybutyrate) on a daily basis.

## Claims

### Claim 1

A composition consisting essentially of:
(a) purified butyrate or esters or propionate salts thereof; and
(b) purified beta-hydroxybutyrate or esters or propionate salts thereof.

### Claim 2 (depends on 1)

The composition of claim 1, which further comprises an agent selected from the group consisting of acetyl-L carnitine, R-alpha lipoic acid, and green tea extract.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the purified butyrate includes a butyrate sodium salt, a butyrate calcium salt, and a butyrate magnesium salt; and the purified beta-hydroxybutyrate includes beta-hydroxybutyrate sodium salt, beta-hydroxybutyrate calcium salt, and beta-hydroxybutyrate magnesium salt.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the total purified butyrate to total purified beta-hydroxybutyrate ratio is about 1:1.

### Claim 5 (depends on 3)

The composition of claim 3, wherein the total purified butyrate to total purified beta-hydroxybutyrate ratio is about 2:1.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the composition is packaged within an oral capsule.

### Claim 7 (depends on 5)

The composition of claim 5, wherein the composition is packaged in powdered form.

### Claim 8 (depends on 5)

The composition of claim 5, which further comprises one or more vitamins.

### Claim 9

A method for providing a person with an exogenous supply of ketones, by orally administering a pharmacologic composition, which is effective to deliver 1000-5000 mg of a short chain fatty acid and 1000-10,000 mg of ketone on a daily basis.

### Claim 10 (depends on 9)

The method of claim 9, wherein the short chain fatty acid is butyrate and the ketone is beta-hydroxybutyrate.

### Claim 11 (depends on 10)

The method of claim 10, wherein the pharmacologic composition consists essentially of:
(a) purified butyrate or esters or propionate salts thereof; and
(b) purified beta-hydroxybutyrate or esters or propionate salts thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein the pharmacologic composition further comprises an agent selected from the group consisting of acetyl-L carnitine, R-alpha lipoic acid, and green tea extract.

### Claim 13 (depends on 12)

The method of claim 12, wherein the purified butyrate includes a butyrate sodium salt, a butyrate calcium salt, and a butyrate magnesium salt; and the purified beta-hydroxybutyrate includes beta-hydroxybutyrate sodium salt, beta-hydroxybutyrate calcium salt, and beta-hydroxybutyrate magnesium salt.

### Claim 14 (depends on 13)

The method of claim 13, wherein the total purified butyrate to total purified beta-hydroxybutyrate ratio is about 1:1.

### Claim 15 (depends on 13)

The method of claim 13, wherein the total purified butyrate to total purified beta-hydroxybutyrate ratio is about 2:1.

### Claim 16 (depends on 13)

The method of claim 13, wherein the pharmacologic composition is packaged within an oral capsule.

### Claim 17 (depends on 13)

The method of claim 13, wherein the pharmacologic composition is packaged in powdered form.

### Claim 18 (depends on 13)

The method of claim 13, wherein the pharmacologic composition further comprises one or more vitamins.

### Claim 19 (depends on 9)

The method of claim 9, wherein the pharmacologic composition is effective to deliver 2000-5000 mg of a short chain fatty acid and 5000-10,000 mg of ketone on a daily basis.
